ASOA and ASCRS hosted the inaugural Business of Interventional Glaucoma program on Thursday, April 24, bringing together administrators, surgeons, and industry to gain a better understanding of how to efficiently, effectively, and profitably adopt an interventional glaucoma approach in practice.
“It’s the most righteous of offerings, and it also happens to be one that is profitable,” said Matt Jensen, former administrator and CEO of Vance Thompson Vision, kicking off the program. “Industry has great technologies, but if they never reach the patient, then shame on us.”
Mr. Jensen said from his research, “interventional glaucoma (IG)” was first published on in 2015. He said IG is a mindset, a philosophy, but he added that it’s more important than just a way of thinking.
Drops are a mainline glaucoma treatment for most patients with this disease, but for various reasons, patients are not compliant. He cited data that patients who are offered drops as their main treatment are two times more likely to lapse in their care. “There is unmanaged disease going on, and we think this is a travesty. How do we arrest this trend?” Mr. Jensen said.
This is where interventional glaucoma therapies come in. Not only are they ethical for the patient, Mr. Jensen said, but they can help practices grow.
Sessions within the program included “Understanding the Need: EthIGs & EconomIGs,” “Business of Glaucoma,” “Billing & Compliance,” Patient Education & Execution,” and “What’s Next?”
The Business of Interventional Glaucoma program was sponsored at the Diamond Level by Glaukos and at the Gold Level by AbbVie, Bausch + Lomb, Brevium, Marjen, Navigate, Nextech, and Sight Sciences.
Source: ASCRS
